TABLE 2.
Association between fat mass to lean body mass ratio and all-cause mortality using Cox proportional hazard regression.a
| <60 years |
P for trend | ≥60 years |
P for trend | |||||
| T1 | T2 | T3 | T1 | T2 | T3 | |||
| Female | ||||||||
| Unadjusted model | 1 | 0.77 (0.53, 1.11) | 0.72 (0.49, 1.06) | 0.172 | 1 | 0.84 (0.57, 1.24) | 0.74 (0.51, 1.07) | 0.282 |
| Model Ab | 1 | 0.79 (0.55, 1.15) | 0.69 (0.47, 1.02) | 0.159 | 1 | 0.95 (0.64, 1.41) | 0.83 (0.57, 1.22) | 0.624 |
| Model Bb | 1 | 0.99 (0.67, 1.46) | 0.84 (0.56, 1.26) | 0.661 | 1 | 1.07 (0.71, 1.61) | 0.96 (0.64, 1.44) | 0.857 |
| Model Cb | 1 | 1.04 (0.66, 1.64) | 0.95 (0.57, 1.56) | 0.935 | 1 | 1.30 (0.82, 2.07) | 1.10 (0.69, 1.75) | 0.521 |
| Model Db | 1 | 0.86 (0.48, 1.54) | 0.66 (0.34, 1.30) | 0.486 | 1 | 2.08 (1.08, 4.01) | 0.90 (0.45, 1.81) | 0.018 |
| Male | ||||||||
| Unadjusted model | 1 | 0.83 (0.59, 1.18) | 0.87 (0.60, 1.25) | 0.549 | 1 | 0.58 (0.42, 0.79) | 0.66 (0.50, 0.88) | 0.001 |
| Model Ab | 1 | 0.84 (0.59, 1.20) | 0.88 (0.61, 1.28) | 0.610 | 1 | 0.58 (0.43, 0.80) | 0.63 (0.47, 0.84) | 0.001 |
| Model Bb | 1 | 0.86 (0.60, 1.23) | 0.99 (0.67, 1.44) | 0.682 | 1 | 0.57 (0.42, 0.79) | 0.62 (0.46, 0.84) | 0.001 |
| Model Cb | 1 | 0.80 (0.51, 1.27) | 1.00 (0.64, 1.57) | 0.569 | 1 | 0.65 (0.45, 0.94) | 0.66 (0.46, 0.95) | 0.033 |
| Model Db | 1 | 0.98 (0.54, 1.78) | 1.25 (0.72, 2.17) | 0.653 | 1 | 0.74 (0.46, 1.20) | 0.84 (0.53, 1.33) | 0.475 |
aValues are models adjusted HR and 95% confidence interval, ranges for tertiles (T) 1 through 3. Linear trends (p for trend) were obtained with the ratio of fat mass to lean body mass as continuous variables.
bModel A: adjusted for age, education, smoking, alcohol drinking, family history of cancer, version of Body Composition Analyzer; Model B: as model A and additionally adjusted for Karnofsky performance scores, duration of hospital stays, NRS 2002 score, nutrition support, and handgrip strength; Model C: as Model B and additionally adjusted for commodities, previous treatments, cancer types, TNM stages, and quality of life; Model D: as Model C and additionally adjusted C-reaction protein.